Study Summary
A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Interested in this trial?
Submit an InquiryInterventions
CAR-T cells chimeric antigen receptor T cellsDRUG
Conditioning regimen:
Days -9 to -3:
Venetoclax administered with a target dose of 200 mg/day.
Days -5 to -4:
Cytarabine administered at 500 mg/m²/day.
Days -5 to -3:
Cyclophosphamide at 300 mg/m²/day plus Fludarabine at 30 mg/m²/day.
Day 0:
Infusion of CT0890B CAR-T cells at one of four dose levels using an i3+3 Dose-Escalation Design:
1.5 × 10⁸ total cells, 3.0 × 10⁸ total cells, 4.5 × 10⁸ total cells, 6.0 × 10⁸ total cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Peking University People's Hospital | Beijing | China |